Results 201 to 210 of about 53,459 (315)

A pediatric nasopharyngeal carcinoma masquerading as Kimura disease: a rare case report from Nepal. [PDF]

Int J Surg Case Rep
Mandal S, Pant A, Shah AK, Paudel S, Panthi B, Shakya BR.   +5 more
europepmc   +1 more source

Effects of intraduodenally applied bile salts on pancreatic secretion [PDF]

, 1993
Lehnert, Peter, Riepl, Rudolf L.
core   +1 more source

DNA Virus Detection in Olfactory Neuroblastomas Using Targeted Enrichment NGS

Neuropathology, Volume 46, Issue 2, April 2026.
ABSTRACT A variety of malignancies can be found in the sinonasal tract including the nasal cavity, paranasal sinuses, and skull base. Many of these are attributed to viruses, for example, carcinomas with the presence of transcriptionally active high‐risk human papillomavirus, as well as Epstein–Barr virus associated malignant lymphoepithelial carcinoma
Maria K. Jauhiainen, Outi I. Mielonen, Aaro Haapaniemi, Maria Söderlund‐Venermo, Jaana Hagström, Maria F. Perdomo, Saku T. Sinkkonen, Antti A. Mäkitie   +7 more
wiley   +1 more source

Compassionate boron neutron capture therapy for locally recurrent nasopharyngeal cancer: A retrospective study. [PDF]

J Chin Med Assoc
Wang LW, Hsueh Liu YW, Peir JJ, Lin KH, Lee JC, Shueng PW, Yen SH, Yang MH.   +7 more
europepmc   +1 more source

A phase 1 study of berzosertib (M6620, VX‐970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)

Cancer, Volume 132, Issue 6, 15 March 2026.
ABSTRACT Background Ataxia telangiectasia Rad3‐related (ATR) protein kinase regulates DNA damage response and is essential for tumor cell survival. Preclinically, ATR inhibition can sensitize tumor cells to radiation and chemotherapy. The authors conducted a phase 1 trial of berzosertib, a selective ATR inhibitor, in combination with definitive ...
Aarti Bhatia, Zhengjia Chen, Yuji Zhang, Justine Yang Bruce, Susanne Arnold, Varinder Kaur, Jonathan W. Riess, Moon Fenton, Barbara Burtness, Nabil F. Saba, Harold Tara, Conor E. Steuer, Dong M. Shin, Garrett Wasp, Thomas H. Davis, Malini Patel, John C. Schmitz, Priyanka Bhateja, Virginia Diavolitsis, Dan P. Zandberg, Darrion L. Mitchell, Brian F. Kiesel, Charles Kunos, Steven D. Gore, Michael Carducci, Jan H. Beumer, Taofeek K. Owonikoko   +26 more
wiley   +1 more source

Discontinuation of immunotherapy and its effect on prognosis in recurrent or metastatic nasopharyngeal carcinoma patients: a retrospective analysis. [PDF]

Cancer Immunol Immunother
Peng Y, Chu X, Zha D, Meng L, Yao J, Liu T, Liu Q, Xu X, Wang S, Chen M, You R, Liu Y.   +11 more
europepmc   +1 more source

Regulation of pyruvate dehydrogenase complex: Dancing to different drums in cancer

International Journal of Cancer, Volume 158, Issue 6, Page 1464-1480, 15 March 2026.
Abstract Mechanisms governing the regulation of pyruvate dehydrogenase complex (PDC) are markedly modified in cancer cells compared to normal cells. PDC activity in normal cells is controlled by the reversible phosphorylation of three serine residues by dedicated kinases and phosphatases.
Mulchand S. Patel, Todd C. Rideout
wiley   +1 more source

Prediction of the disease burden of nasopharyngeal carcinoma in China: A comparative analysis of ARIMA, LSTM, and DNN models. [PDF]

Medicine (Baltimore)
Chen Y, Zhang K, Luo J.
europepmc   +1 more source

Generalizability of deep learning–based dose conversion model in proton beam therapy

Journal of Applied Clinical Medical Physics, Volume 27, Issue 3, March 2026.
Abstract Background In proton beam therapy (PBT), the analytical pencil beam (PB) algorithm involves dose uncertainties in inhomogeneous regions, making accurate Monte Carlo (MC) dose calculation desirable but time‐consuming. Deep learning, converting the dose calculated by the PB algorithm into an MC‐equivalent dose distribution, can resolve the trade‐
Ryohei Kato, Noriyuki Kadoya, Takahiro Kato, Ryota Tozuka, Shuta Ogawa, Masao Murakami, Keiichi Jingu   +6 more
wiley   +1 more source

Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial. [PDF]

BMJ
You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, Liu LZ, Zhang WJ, Liu Q, Li HF, Ouyang YF, Duan XT, Wang Q, Peng L, Liang JL, Feng ZK, Qin ZH, Liu X, He ZK, Zhang B, Long GX, Jiang YH, Lei F, Huang PY, Hua YJ, Chen MY.   +29 more
europepmc   +1 more source